According to filings with the U.S. Securities and Exchange Commission, iVEAcare is raising up to $27,575,835.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Todd Kerkow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About iVEAcare
iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations. At iVEAcare, we are focused on developing and commercializing next generation neuromodulation technology platforms to treat patients suffering from chronic diseases. We are serial entrepreneurs, investors, and operators with extensive experience in implantable medical devices who have successfully founded multiple companies in the bioelectronics space. We partner with leading physicians to solve burdening chronic conditions and are supported by venture capital partners with deep domain expertise.

To learn more about iVEAcare, visit http://iveacare.com/

Contact:
Todd Kerkow, President and Chief Executive Officer
651-269-4639
https://www.linkedin.com/in/todd-kerkow-3394b16/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.